Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease

Summary Background Anti‐TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases. Aim To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis...

Ausführliche Beschreibung